Subcutaneous therapeutic use of dpp-4 inhibitor

摘要

Disclosed is the use of linagliptin and one of a GLP-1 analogue having a short half-life or native GLP-1, for the manufacture of a medicament, effective in the treatment of obesity or overweight or for reducing body weight in a subject in need thereof, wherein the medicament is administered subcutaneously.